However, given the limitations of past randomized trials on the topic and the advantages of oral agents over insulin for treatment of GDM, including greater ease of use and acceptance among patients, more well-designed studies that include information on longer-term safety outcomes for pregnant individuals and children are urgently needed. This evidence concerns the gene INS and gestational diabetes.